Aliases & Classifications for Hemarthrosis

MalaCards integrated aliases for Hemarthrosis:

Name: Hemarthrosis 12 55 44 15 73
Hemarthrosis Involving Pelvic Region and Thigh 12
Haemarthrosis of the Pelvic Region and Thigh 12
Hemarthrosis of the Pelvic Region and Thigh 12
Hemarthrosis Involving Shoulder Region 12
Hemarthrosis Involving Ankle and Foot 12
Hemarthrosis of the Ankle and/or Foot 12
Haemarthrosis of the Ankle and Foot 12
Hemarthrosis of the Shoulder Region 12
Hemarthrosis of the Ankle and Foot 12
Hemarthrosis of Ankle and/or Foot 12
Hemarthrosis Involving Lower Leg 12
Hemarthrosis Involving Upper Arm 12
Haemarthrosis of Shoulder Joint 12
Hemarthrosis of Shoulder Region 12
Hemarthrosis Involving Forearm 12
Hemarthrosis of the Lower Leg 12
Hemarthrosis of the Upper Arm 12
Hemarthrosis Involving Hand 12
Hemarthrosis of the Forearm 12
Hemarthrosis of Lower Leg 12
Hemarthrosis of Upper Arm 12
Hemarthrosis of Shoulder 12
Hemarthrosis of the Hand 12
Hemarthrosis of Forearm 12
Hemarthrosis of Hand 12

Classifications:



External Ids:

Disease Ontology 12 DOID:801
ICD10 33 M25.0
ICD9CM 35 719.1 719.10
MeSH 44 D006395
UMLS 73 C0018924

Summaries for Hemarthrosis

MalaCards based summary : Hemarthrosis, also known as hemarthrosis involving pelvic region and thigh, is related to afibrinogenemia, congenital and factor x deficiency, and has symptoms including arthralgia, hemoptysis and metatarsalgia. An important gene associated with Hemarthrosis is F8 (Coagulation Factor VIII), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Bevacizumab and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, b cells and monocytes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Hemarthrosis (or haemarthrosis) is a bleeding into joint spaces. It is a common feature of... more...

Related Diseases for Hemarthrosis

Diseases related to Hemarthrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 afibrinogenemia, congenital 31.4 F8 VWF
2 factor x deficiency 30.4 F10 F7 F9 VWF
3 factor vii deficiency 30.1 F10 F7 F8 F9
4 vitamin k deficiency hemorrhagic disease 30.0 BGLAP F8
5 acquired hemophilia 29.9 F10 F8 F9
6 glanzmann thrombasthenia 29.3 F8 F9 VWF
7 arthropathy 29.2 F8 F9
8 von willebrand's disease 29.1 F8 F9 VWF
9 factor v deficiency 29.0 F10 F7 F8 F9 VWF
10 hemophilia 28.7 F7 F8 F9 VWF
11 hemophilia b 28.2 F10 F7 F8 F9
12 hemophilia a 27.6 F10 F7 F8 F9 VWF
13 myocardial infarction 27.2 F10 F13A1 F7 F8 VWF
14 hemorrhagic disease 27.1 F10 F7 F8 F9 VWF
15 acquired hemophilia a 10.5 F8 F9
16 cardiac tamponade 10.4 F8 F9
17 x-linked disease 10.3 F8 F9
18 factor xiii deficiency 10.3 F13A1 F8
19 papillary cystadenocarcinoma 10.2 BGLAP SPP1
20 fainting 10.2 F8 VWF
21 indeterminate leprosy 10.2 F13A1 F8
22 von willebrand disease, type 3 10.2 F8 VWF
23 cerebral arteritis 10.2 F8 VWF
24 von willebrand disease, type 1 10.2 F8 VWF
25 hypophosphatasia, adult 10.2 BGLAP SPP1
26 factor viii deficiency 10.2 F8 VWF
27 pulmonary embolism 10.2 F10 F9
28 intracranial thrombosis 10.2 F8 VWF
29 lymphangiosarcoma 10.1 F8 VWF
30 nephrogenic systemic fibrosis 10.1 F13A1 SPP1
31 osteofibrous dysplasia 10.1 BGLAP SPP1
32 factor xii deficiency 10.1 F9 VWF
33 synovitis 10.1
34 arthritis 10.0
35 bone resorption disease 10.0 BGLAP SPP1
36 aortic valve disease 1 9.9 SPP1 VWF
37 factor xi deficiency 9.9
38 acute myocardial infarction 9.9
39 thrombasthenia 9.9
40 aneurysm 9.9
41 mild hemophilia a 9.9 F10 F8 VWF
42 malignant skin fibrous histiocytoma 9.9 F7 F9
43 afibrinogenemia 9.8 F10 F8 VWF
44 malignant dermis tumor 9.8 F7 F9
45 blood platelet disease 9.8 F10 F8 VWF
46 osteoarthritis 9.8
47 pigmented villonodular synovitis 9.8
48 purpura 9.8
49 villonodular synovitis 9.8
50 acquired von willebrand syndrome 9.8 F8 F9 VWF

Graphical network of the top 20 diseases related to Hemarthrosis:



Diseases related to Hemarthrosis

Symptoms & Phenotypes for Hemarthrosis

UMLS symptoms related to Hemarthrosis:


arthralgia, hemoptysis, metatarsalgia, other symptoms referable to joint, stiffness of joint, not elsewhere classified in icd10cm

MGI Mouse Phenotypes related to Hemarthrosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.63 F9 SPP1 VWF F10 F13A1 F7
2 homeostasis/metabolism MP:0005376 9.5 F9 SPP1 VWF F10 F13A1 F7
3 mortality/aging MP:0010768 9.17 F9 SPP1 VWF F10 F13A1 F7

Drugs & Therapeutics for Hemarthrosis

Drugs for Hemarthrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
5
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
6
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
Racepinephrine Approved Phase 4 329-65-7 838
9 tannic acid Approved, Nutraceutical Phase 4,Phase 3
10 Factor VIII Phase 4,Phase 3,Phase 2,Not Applicable
11 Coagulants Phase 4,Phase 3,Phase 2,Not Applicable
12 Hemostatics Phase 4,Phase 2,Not Applicable
13 Angiogenesis Inhibitors Phase 4
14 Angiogenesis Modulating Agents Phase 4
15 triamcinolone acetonide Phase 4
16 Adjuvants, Immunologic Phase 4,Not Applicable
17 Triamcinolone diacetate Phase 4
18 Triamcinolone hexacetonide Phase 4
19 Viscosupplements Phase 4,Not Applicable
20 Hylan Phase 4
21 Protective Agents Phase 4,Not Applicable
22 Analgesics Phase 4
23 Respiratory System Agents Phase 4
24 Central Nervous System Depressants Phase 4
25 Adrenergic Agents Phase 4
26 Adrenergic Agonists Phase 4
27 Adrenergic alpha-Agonists Phase 4
28 Adrenergic beta-Agonists Phase 4
29 Mydriatics Phase 4
30 Narcotics Phase 4
31 Neurotransmitter Agents Phase 4
32 Anesthetics Phase 4
33 Anesthetics, Local Phase 4
34 Vasoconstrictor Agents Phase 4
35 Anti-Asthmatic Agents Phase 4
36 Peripheral Nervous System Agents Phase 4
37 Epinephryl borate Phase 4
38 Autonomic Agents Phase 4
39 Bronchodilator Agents Phase 4
40
Thrombin Approved, Investigational Phase 3,Not Applicable
41 Immunoglobulin Fc Fragments Phase 3
42 Antibodies Phase 3
43 Immunoglobulins Phase 3
44 Antibodies, Bispecific Phase 3
45
Rivaroxaban Approved Phase 2 366789-02-8
46
Apixaban Approved Phase 2 503612-47-3 10182969
47
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
48
protease inhibitors Phase 2
49 Serine Proteinase Inhibitors Phase 2
50 HIV Protease Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Unknown status NCT02060305 Phase 4 Bevacizumab intra-articular injection
2 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
3 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
4 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
5 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
6 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Completed NCT00586521 Phase 4 Kogenate (BAY14-2222)
7 Viscosupplementation in Patients With Hemophilic Arthropathy Completed NCT01748201 Phase 4
8 Russian Kogenate Pediatric Study Completed NCT00632814 Phase 4 rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
9 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A Completed NCT01810666 Phase 4
10 Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy Completed NCT00638001 Phase 4
11 Canadian Hemophilia Prophylaxis Study Completed NCT01085344 Phase 4
12 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens Completed NCT00927667 Phase 4
13 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A Completed NCT02697370 Phase 4 Pharmacokinetic based dosage change
14 China ADVATE PTP Study Completed NCT02170402 Phase 4
15 Effect of Local Anesthetic Injection and Hemarthrosis Aspiration on Pain and Narcotic/Opioid Analgesia Use-Tibial Plateau Fractures Recruiting NCT02951884 Phase 4 Bupivacaine with Epinephrine
16 A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children Recruiting NCT02999308 Phase 4
17 Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B Completed NCT00364182 Phase 3 Recombinant Coagulation Factor IX (BeneFIX);Recombinant Coagulation Factor IX (BeneFIX)
18 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A Completed NCT01458106 Phase 3 BIIB031 (rFVIIIFc);FVIII (PK subgroup only)
19 Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B Completed NCT01440946 Phase 3 rFIXFc;FIX
20 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A Completed NCT01181128 Phase 3 Factor VIII (rFVIIIFc);Advate®
21 Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A Completed NCT01454739 Phase 3 rFVIIIFc
22 Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B Completed NCT01425723 Phase 3
23 Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor Completed NCT00851721 Phase 3
24 Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B Recruiting NCT02234310 Phase 3
25 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors Previously Receiving Bypassing Agent Prophylaxis Recruiting NCT03549871 Phase 3 Fitusiran (ALN-AT3SC)
26 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors Recruiting NCT03417245 Phase 3 fitusiran;factor VIII or factor IX
27 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors Recruiting NCT03417102 Phase 3 fitusiran;recombinant Factor VIIa and FEIBA
28 Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants Recruiting NCT03315455 Phase 3 Emicizumab
29 An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A Recruiting NCT02234323 Phase 3
30 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors Active, not recruiting NCT02622321 Phase 3 Emicizumab;rFVIIa;aPCC
31 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors Active, not recruiting NCT02795767 Phase 3 Emicizumab
32 A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Active, not recruiting NCT02847637 Phase 3 Emicizumab
33 BAX 855 PK-Guided Dosing Active, not recruiting NCT02585960 Phase 3
34 A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A Active, not recruiting NCT01580293 Phase 2, Phase 3
35 Early Prophylaxis Immunologic Challenge (EPIC) Study Terminated NCT01376700 Phase 3
36 rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors Unknown status NCT01105546 Phase 2 recombinant activated factor VII;recombinant activated factor VII
37 Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy Unknown status NCT01629381 Phase 2 Rivaroxaban;placebo
38 Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds Completed NCT00486278 Phase 2 eptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated)
39 Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII Completed NCT00245245 Phase 2 recombinant porcine coagulation factor VIII (OBI-1)
40 A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy Recruiting NCT02994147 Phase 2 Placebo;AC-201CR
41 A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery Recruiting NCT03251482 Phase 2 JNJ-64179375 0.3 mg/kg;JNJ-64179375 0.6 mg/kg;JNJ-64179375 1.2 mg/kg;JNJ-64179375 (Dose to be Determined);JNJ-64179375 A mg/kg;JNJ-64179375 B mg/kg;JNJ-64179375 C mg/kg;JNJ-64179375 D mg/kg;Placebo JNJ-64179375;Apixaban placebo;Apixaban 2.5 mg
42 BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A Terminated NCT00623727 Phase 2
43 Individualized Prophylaxis for Severe Hemophilia A Children Unknown status NCT02116855 Not Applicable
44 The Effect of Functional Activities and Balance Ability With Taping in Subjects of Hemophilia Unknown status NCT02389205 Not Applicable
45 Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia Unknown status NCT02581735
46 Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait. Unknown status NCT02229331
47 Musculoskeletal Function in Hemophilia Unknown status NCT00324493
48 Monitor System for the Safety of Dabigatran Treatment Unknown status NCT02414035
49 Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A Unknown status NCT02282410 Not Applicable ADVATE
50 Adherence to Treatment in Hemophilia Unknown status NCT02191436

Search NIH Clinical Center for Hemarthrosis

Cochrane evidence based reviews: hemarthrosis

Genetic Tests for Hemarthrosis

Anatomical Context for Hemarthrosis

MalaCards organs/tissues related to Hemarthrosis:

41
Bone, B Cells, Monocytes, Myeloid, Skeletal Muscle

Publications for Hemarthrosis

Articles related to Hemarthrosis:

(show top 50) (show all 236)
# Title Authors Year
1
Treatment of Recurrent Hemarthrosis after Total Knee Arthroplasty. ( 29715715 )
2018
2
Severe Ankle Arthritis After Multiple Hemarthrosis Secondary to Factor XI Deficiency: A Case Report. ( 29891129 )
2018
3
Homeopathic Medicine Reduces Pain and Hemarthrosis in Moderate and Severe Hemophilia: A Multicentric Study. ( 29807367 )
2018
4
Endovascular Management of Recurrent Spontaneous Hemarthrosis After Arthroplasty. ( 27882429 )
2017
5
Embolization of the Geniculate Arteries Is an Effective Treatment of Recurrent Hemarthrosis Following Total Knee Arthroplasty That Can Be Safely Repeated. ( 29224993 )
2017
6
Hemarthrosis and scurvy. ( 28433625 )
2017
7
Hemarthrosis subtalar, a rare diagnosis. ( 28409144 )
2017
8
Recurrent Hemarthrosis due to Iatrogenic AVF Treated With Onyx Embolization. ( 28446073 )
2017
9
Spontaneous elbow hemarthrosis identified by point-of-care ultrasound. ( 28435904 )
2017
10
Capsulotomy as a measure to control pain and reducing hemarthrosis in arthroscopic DB ACL reconstruction surgery: a prospective randomized control study. ( 29086025 )
2017
11
Acute hemophilic hemarthrosis: is local cryotherapy recommended? ( 29020808 )
2017
12
Reducing Intra-articular Hemarthrosis After Arthroscopic ACL Reconstruction: Response. ( 26929179 )
2016
13
Reducing Intra-articular Hemarthrosis After Arthroscopic ACL Reconstruction: Letter to the Editor. ( 26929178 )
2016
14
Acute Hemarthrosis of the Knee Caused by Arteriovenous Malformation. ( 27231206 )
2016
15
Technically Successful Geniculate Artery Embolization Does Not Equate Clinical Success for Treatment of Recurrent Knee Hemarthrosis after Knee Surgery. ( 26806692 )
2016
16
Geniculate Artery Embolization for Management of Recurrent Hemarthrosis: A Single-Center Experience. ( 27338503 )
2016
17
Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. ( 28039188 )
2016
18
Spontaneous Recurrent Hemarthrosis of the Knee: A Report of Two Cases with a Source of Bleeding Detected during Arthroscopic Surgery of the Knee Joint. ( 27703824 )
2016
19
Spontaneous Hemarthrosis of the Knee - Late Complication of Flexible Femur Nailing: A Case Report. ( 28180118 )
2016
20
Epidemiology of intra- and peri-articular structural injuries in traumatic knee joint hemarthrosis - data from 1145 consecutive knees with subacute MRI. ( 27374877 )
2016
21
Effects of hemarthrosis on cartilage and synovium in rabbits. ( 26936196 )
2016
22
Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data. ( 25729030 )
2015
23
LASER versus electromagnetic field in treatment of hemarthrosis in children with hemophilia. ( 26306883 )
2015
24
Geniculate artery embolization for recurrent postarthroplasty hemarthrosis of the knee. ( 27398122 )
2015
25
Reducing Intra-articular Hemarthrosis After Arthroscopic Anterior Cruciate Ligament Reconstruction by the Administration of Intravenous Tranexamic Acid: A Prospective, Randomized Controlled Trial. ( 26337246 )
2015
26
Recurrent Hemarthrosis Following Knee Arthroplasty Treated with Arterial Embolization. ( 26092252 )
2015
27
Occult Intra-articular Knee Injuries in Children With Hemarthrosis. ( 24753236 )
2014
28
Anticoagulant-induced hemarthrosis presenting as anterior shoulder dislocation. ( 25043625 )
2014
29
Spontaneous hemarthrosis following fibrinolytic therapy for acute myocardial infarction: a case report and literature review. ( 25417208 )
2014
30
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease. ( 24418945 )
2014
31
Selective arterial embolization with gelatin particles for refractory knee hemarthrosis. ( 23846552 )
2013
32
Recurrent hemarthrosis : an unusual cause. ( 23680622 )
2013
33
Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. ( 24283895 )
2013
34
Recurrent hemarthrosis after total knee arthroplasty caused by the impingement of a remnant lateral meniscus: A case report. ( 24231622 )
2013
35
Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization. ( 24252538 )
2013
36
A case of selective arterial embolization for recurrent hemarthrosis after total knee arthroplasty. ( 22237971 )
2013
37
Geniculate artery embolization in the management of spontaneous recurrent hemarthrosis of the knee: case series. ( 23433418 )
2013
38
A case of bilateral hemarthrosis due to pseudoaneurysms in a patient on anticoagulation therapy. ( 23669803 )
2013
39
Hemophilic chronic synovitis: therapy of hemarthrosis using endovascular embolization of knee and elbow arteries. ( 23150120 )
2013
40
MRI findings in adolescent patients with acute traumatic knee hemarthrosis. ( 23147616 )
2012
41
Transarterial embolization for the management of hemarthrosis of the knee. ( 22154590 )
2012
42
Intra-articular nodular fasciitis of the knee: a rare cause of recurrent hemarthrosis. ( 21431289 )
2012
43
Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin. ( 22764328 )
2012
44
Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)--a cross-sectional analysis. ( 22874525 )
2012
45
Knee hemarthrosis after arthroscopic surgery in an athlete with low factor XIII activity. ( 23031577 )
2012
46
Spontaneous recurrent hemarthrosis of the knee joint in the elderly: a report of two cases. ( 21607723 )
2012
47
Trauma resulting in hemarthrosis and long medial collateral ligament desmitis of the tarsocrural joint in a horse. ( 22043073 )
2011
48
Recurrent hemarthrosis after unicompartmental knee arthroplasty. ( 21902161 )
2011
49
Magnetic resonance angiography in the management of recurrent hemarthrosis after total knee arthroplasty. ( 21397454 )
2011
50
Does the source of hemarthrosis influence posttraumatic joint contracture and biomechanical properties of the joint? ( 21420211 )
2011

Variations for Hemarthrosis

Expression for Hemarthrosis

Search GEO for disease gene expression data for Hemarthrosis.

Pathways for Hemarthrosis

Pathways related to Hemarthrosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 F10 F13A1 F7 F8 F9 VWF
2
Show member pathways
12.44 F10 F13A1 F7 F8 F9
3
Show member pathways
11.63 F10 F13A1 F7 F8 F9 VWF
4
Show member pathways
11.59 BGLAP F10 F7 F9
5 11.24 F10 F13A1 F7 F8 F9 VWF
6 11.13 BGLAP SPP1
7 11.09 BGLAP SPP1
8 11 BGLAP SPP1
9 10.63 BGLAP F10 F7 F9

GO Terms for Hemarthrosis

Cellular components related to Hemarthrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 BGLAP F7 F8 F9 SPP1
2 extracellular region GO:0005576 9.56 BGLAP F10 F13A1 F7 F8 F9
3 vesicle GO:0031982 9.5 BGLAP F7 SPP1
4 Golgi lumen GO:0005796 9.46 BGLAP F10 F7 F9
5 platelet alpha granule lumen GO:0031093 9.43 F13A1 F8 VWF
6 endoplasmic reticulum lumen GO:0005788 9.1 BGLAP F10 F7 F8 F9 SPP1

Biological processes related to Hemarthrosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 ER to Golgi vesicle-mediated transport GO:0006888 9.8 BGLAP F10 F7 F8 F9
2 platelet degranulation GO:0002576 9.63 F13A1 F8 VWF
3 blood coagulation GO:0007596 9.63 F10 F13A1 F7 F8 F9 VWF
4 signal peptide processing GO:0006465 9.62 BGLAP F10 F7 F9
5 blood coagulation, intrinsic pathway GO:0007597 9.56 F10 F8 F9 VWF
6 blood coagulation, extrinsic pathway GO:0007598 9.54 F10 F7 F9
7 response to estrogen GO:0043627 9.52 BGLAP F7
8 response to nutrient levels GO:0031667 9.51 BGLAP F7
9 biomineral tissue development GO:0031214 9.49 BGLAP SPP1
10 response to vitamin D GO:0033280 9.48 BGLAP SPP1
11 response to vitamin K GO:0032571 9.43 BGLAP F7
12 peptidyl-glutamic acid carboxylation GO:0017187 9.26 BGLAP F10 F7 F9
13 hemostasis GO:0007599 9.1 F10 F13A1 F7 F8 F9 VWF

Molecular functions related to Hemarthrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.33 F10 F7 F9
2 endopeptidase activity GO:0004175 9.26 F7 F9
3 calcium ion binding GO:0005509 9.26 BGLAP F10 F7 F9
4 serine-type peptidase activity GO:0008236 8.8 F10 F7 F9

Sources for Hemarthrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....